Latest Overdiagnosis Stories
A model used to estimate breast cancer survival rates found that the probability that a woman with screen-detected breast cancer will avoid a breast cancer death because of screening mammography may be lower than previously thought.
In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened.
The introduction of multidetector row computed tomographic pulmonary angiography (CTPA) was associated with an apparent increase in the diagnosis of pulmonary embolism (PE), but with only minimal changes in mortality (death), suggesting the possibility of overdiagnosis.
Screening does not significantly reduce prostate cancer deaths, but the risk of overdetection and overtreatment is considerable, concludes a 20-year study published on bmj.com today.
Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time â€” known as PSA velocity â€” is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.
Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen (PSA) level and low-risk disease.
MARLTON, N.J., March 23 /PRNewswire/ -- The words "you have prostate cancer" leave patients and their families in shock, confusion and fear.
Data Addresses the Central Challenge in Prostate Cancer Care as Identified by March 4 Congressional Hearing and Highlights Need for Further Research WASHINGTON, March 9 /PRNewswire-USNewswire/ -- New preliminary data from a pilot study in the Netherlands indicates that imaging tools may help address the most challenging clinical dilemma of prostate cancer care as identified by the hearing of the House Oversight and Government Reform Committee and its expert witnesses last week: to treat or...
The PRIME Act Follows Historic Congressional Hearing Which Highlighted Lack of Accurate Prostate Diagnostics WASHINGTON, March 9 /PRNewswire-USNewswire/ -- AdMeTech President and CEO Dr. Faina Shtern and Oscar-winning actor Louis Gossett, Jr. today praised Rep.
- A hairdresser.